DAX+0,26 % EUR/USD+0,10 % Gold-0,33 % Öl (Brent)-0,78 %

ANALYSE: Akorn-Aktie möglicherweise vor noch größerem Absturz - Raymond James (Seite 11) | Diskussion im Forum



Begriffe und/oder Benutzer

 

Akorn Receives FDA Warning Letter
http://investors.akorn.com/news-releases/news-release-detail…

=>
...Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, announced that it received a warning letter from the U.S. Food and Drug Administration (FDA) related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.

Akorn is committed to the highest standards of quality and compliance, and will continue to work collaboratively with the FDA to resolve all issues addressed in the warning letter. The Company will respond to the FDA letter within the required 15 working days from receipt of the letter....
Akorn | 4,138 €
Antwort auf Beitrag Nr.: 60.886.584 von faultcode am 25.06.19 15:16:23Akorn auf dem Weg zurück zur alten Kampflinie bei ~USD6.6

Akorn | 5,260 $
Antwort auf Beitrag Nr.: 60.914.265 von faultcode am 28.06.19 16:12:15
Akorn Provides Preliminary Second Quarter 2019 Results
http://investors.akorn.com/news-releases/news-release-detail…

LAKE FOREST, Ill., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its preliminary financial results for the second quarter of 2019.

Second Quarter 2019 and Recent Business Highlights

• Net revenue was $178 million, up 7% from the first quarter of 2019, down 7% from the prior year quarter
• Net loss was $112 million, compared to $82 million in the first quarter of 2019 and $88 million in the prior year quarter
• Adjusted EBITDA was $22 million, compared to $10 million in the first quarter of 2019 and $35 million in the prior year quarter
• Generated positive operating cash flow during the second quarter
• Continued sequential reduction in backorders and failure to supply penalties
Launched three products: TheraTears® SteriLid® Antimicrobial, the first FDA Accepted Antimicrobial Eyelid Cleanser, Loteprednol Etabonate Ophthalmic Suspension, 0.5%, and Dicyclomine Hydrochloride Injection, USP
• Received three ANDA approvals: Loteprednol Etabonate Ophthalmic Suspension, 0.5%, Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC), and Azelastine Hydrochloride Nasal Spray, 0.1%
• Responded to FDA warning letter related to the 2018 inspection of our Somerset, NJ manufacturing facility
Reached non-binding agreement in principle with lead plaintiffs in the securities class action litigation

See "Non-GAAP Financial Measures" below.

Douglas Boothe, Akorn’s President and Chief Executive Officer, stated, “We are pleased that our second quarter results showed continued financial and operational improvements across the business, a strong signal that our operational initiatives are creating value and generating momentum. We saw reductions in backorders and failure to supply penalties, which have a direct impact on both financial performance and customer satisfaction.”

Boothe continued, “As we look to the second half of 2019, we feel confident in the fundamentals of our business and believe that our focus on compliance, transparency, and accountability will allow us to execute against our strategic growth objectives.

As such, we are updating our net loss guidance and affirming our net revenue and adjusted EBITDA guidance for the full year of 2019 as we strive to return the Company to a path of long-term profitable growth for our stakeholders.”

....
(FC: Format)
Akorn | 3,356 €
Antwort auf Beitrag Nr.: 61.152.113 von faultcode am 01.08.19 13:57:14nächstes Ziel mMn: USD6..7

--> aus der Q2-Präsentation:



-->
• die großen Hedgies sind alle raus
• die anderen sind gebrannte Kinder
• ...und der Rest traut sich nicht

• die Shorties bauten zuletzt ab, liegen aber immer noch höher als Ende 2018 :eek: --> https://www.nasdaq.com/market-activity/stocks/akrx/short-int…

=> nur die beinharten sind z.Z. (long) drin ;)


--> ich überlege, vor Q3 nachzukaufen: 31.10.? -- noch unbestätigt
Akorn | 4,065 $
https://www.akorn2019securitiessettlement.com/documents --> Proof of Claim and Release Form

--> oben kann man mit Hilfe der Form PROOF OF CLAIM AND RELEASE bis zum 24.1.2020 eventuelle Ansprüche an den SETTLEMENT FUND geltend machen, wenn man Akorn-Aktien vom NOVEMBER 3, 2016 bis APRIL 8, 2019 hatte, bzw. erworben hatte - und eine ganze Reihe von Bedingungen erfüllt sind
Akorn | 4,118 €
Antwort auf Beitrag Nr.: 61.700.329 von faultcode am 15.10.19 23:49:04
Zitat von faultcode: ...--> ich überlege, vor Q3 nachzukaufen: 31.10.? -- noch unbestätigt

-->
... it plans to issue a press release before market open on Thursday, October 31, 2019 outlining its third quarter 2019 financial results.
http://investors.akorn.com/news-releases/news-release-detail…
Akorn | 4,870 $
Antwort auf Beitrag Nr.: 61.791.985 von faultcode am 29.10.19 18:47:49
Akorn Provides Preliminary Third Quarter 2019 Results
31.10.
http://investors.akorn.com/news-releases/news-release-detail…

Updates net loss and affirms net revenue and adjusted EBITDA guidance

LAKE FOREST, Ill., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its preliminary financial results for the third quarter of 2019.

Third Quarter 2019 and Recent Business Highlights

• Net revenue was $176 million, up $11 million, 6% from the prior year quarter
• Net income was $48 million, compared to $70 million loss in the prior year quarter
• Adjusted EBITDA was $29 million, compared to $10 million in the prior year quarter
• Generated positive operating cash flow during the third quarter
• Launched five new products year-to-date including one in the third quarter: Diclofenac Sodium Topical Gel 1%
• Received five ANDA approvals year-to-date including two in the third quarter: Azelastine Hydrochloride Nasal Spray, 0.15% and Betamethasone Dipropionate Lotion USP (Augmented), 0.05%
• Continued progress on operational initiatives leading to stability in backorders and significant reduction in failure to supply penalties

...

=> zack!

Akorn | 4,303 €
 Durchsuchen


Beitrag zu dieser Diskussion schreiben